112,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
  • Gebundenes Buch

This integrated book covers the entire spectrum of cancer biomarkers in development and clinical use. Predictive and prognostic markers are explored in the context of colon cancer, breast cancer, lung cancer, prostate cancer, and GIST. International experts provide insight into toxicity markers and surrogate markers. Attention is also given to biomarker assay development, validation, and strategies.
A powerful tool for determining decisions on therapy, selecting drug regimens, monitoring the efficacy of treatment, and performing individualized surveillance, biomarkers represent the
…mehr

Produktbeschreibung
This integrated book covers the entire spectrum of cancer biomarkers in development and clinical use. Predictive and prognostic markers are explored in the context of colon cancer, breast cancer, lung cancer, prostate cancer, and GIST. International experts provide insight into toxicity markers and surrogate markers. Attention is also given to biomarker assay development, validation, and strategies.

A powerful tool for determining decisions on therapy, selecting drug regimens, monitoring the efficacy of treatment, and performing individualized surveillance, biomarkers represent the forefront of cancer research and treatment. As these technologies become increasingly available for clinical use, this book will be an essential resource for oncologists and translational researchers.
Autorenporträt
Heinz-Josef Lenz, MD, FACP, Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033
Rezensionen
From the reviews:

"The new book Biomarkers in Oncology ... has the ambition to provide the overview about identification, development and clinical relevance of biomarkers in solid tumors and hematological malignancies. ... the book represents a valuable source of ideas and inspiration for basic scientists and physician scientists in the innovative translational research in oncology, for those who decide to step forward on the way filling demands of oncological patients." (Jan Sedlak, Neoplasma, Issue 6, 2013)